Boehringer Ingelheim to Acquire Labor Dr. Merk & Kollegen to Strengthen its Next Generation Cancer Immunology Program
Boehringer Ingelheim today announced the execution of the agreement on the acquisition of Labor Dr. Merk & Kollegen. The acquisition will enable Boehringer Ingelheim to further expand and accelerate its comprehensive program for the development of ATMP-based immuno-oncology therapies including the Vesicular Stomatitis Virus (VSV) with modified glycoprotein (GP) platform and cancer vaccines platforms. Labor Dr. Merk & Kollegen has outstanding experience in process development, manufacturing and analytical characterization in virology besides expertise in microbiology and cell culture. Labor Dr. Merk & Kollegen has already worked in close collaboration with Boehringer Ingelheim on viral-based therapy development since 2015.
“The acquisition of Labor Dr. Merk & Kollegen is strengthening our promising pipeline with diverse potential first-in-class cancer immunology and cancer cell directed therapies for patients with hard-to-treat cancer,” said Dr. Michel Pairet, member of Boehringer Ingelheim’s Board of Managing Directors with responsibility for the company’s Innovation Unit. “The trusting and highly effective collaboration between our scientists and the Labor Dr. Merk & Kollegen team has already contributed significantly to our progress in viral-based cancer therapies. We will welcome the Labor Dr. Merk & Kollegen team and look forward to jointly advancing our program in this area.”
Boehringer Ingelheim is taking cancer on by strengthening its position in cancer immunology, with a focus on cancer vaccines, oncolytic viruses, T-cell engagers, stromal modulators and myeloid cell modulators by combining its world-class, in-house research and development with that of highly innovative external companies. The addition of Labor Dr. Merk & Kollegen’s site will enable Boehringer Ingelheim to further strengthen its oncolytic virus and cancer vaccine development capabilities and capacities by establishing an end-to-end fully integrated center of excellence for virus development and clinical manufacturing. It will add to a series of strategic acquisitions and collaborations over the past years, including the acquisition of ViraTherapeutics and AMAL Therapeutics, which are contributing assets that will be further developed at Labor Dr. Merk & Kollegen’s site.
Labor Dr. Merk & Kollegen is a privately-held company founded in 1971. It is headquartered in Ochsenhausen, Germany, close to Boehringer Ingelheim’s Biberach R&D site. As a center of excellence in virology, Labor Dr. Merk & Kollegen has a long track record in GLP and GMP certified biosafety testing. In recent years Labor Dr. Merk & Kollegen established its GMP-virus manufacturing facility. With around 130 highly qualified and specialized employees, the company has built considerable expertise in process development, manufacturing and analytical characterization of viral therapeutics and oncolytic viral therapeutics. Labor Dr. Merk & Kollegen will be integrated with all employees as a new unit into Boehringer Ingelheim’s Development organization and continue to operate at its Ochsenhausen site. A future expansion is planned.
“Following our successful strategic partnership, we are really excited to join forces with Boehringer Ingelheim,” said Dr. Ingrid Rapp, CEO at Labor Dr. Merk & Kollegen. “Boehringer Ingelheim is a truly global pharmaceutical company with excellent R&D capacities. We look forward to taking our next development step in oncology as part of this outstanding team.”
The companies did not disclose the financial terms of the deal. The transaction is subject to the approval of the competition authorities in Germany. Closing will follow thereafter.
Please click on the following link for ‘Notes to Editors’:
http://www.boehringer-ingelheim.com/press-release/agreement-acquire-labor-dr-merk
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201209005383/en/
Contact information
Boehringer Ingelheim
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-90815
press@boehringer-ingelheim.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SFI Health™ Reports Promising Results From a Preliminary Study Evaluating the Impact of Long-Chain Polyunsaturated Fatty Acids on Reading and Writing Skills in Children27.11.2025 09:15:00 EET | Press release
SFI Health™ EMEA, the regional entity of SFI Health™, a global leader in natural healthcare, is proud to announce the publication on Biomedicine of the results of a new study, conducted by the Italian research institute “IRCCS Eugenio Medea” of “La Nostra Famiglia” association, investigating the correlation between long-chain polyunsaturated fatty acids (LCPUFA) and reading and writing abilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251126097656/en/ Italian Research Institute "IRCCS Eugenio Medea" of "La Nostra Famiglia". This investigator-initiated trial is part of an ongoing project investigating the efficacy of omega-3 and omega-6 LCPUFA supplementation to enhance the effects of neuropsychological treatment in children diagnosed with developmental dyslexia (DD). LCPUFAs of the omega-3 group, such as EPA and DHA, play essential roles in microglial activity, neuroinflammatory regulation, and synaptic plasticity—pr
WattCycle Unveils 2025 Black Friday Battery Sales with Europe-Wide Savings on LiFePO4 Batteries27.11.2025 08:00:00 EET | Press release
WattCycle today announces the launch of its Europe-wide Black Friday battery deals 2025, offer up to 60% off for LiFePO4 batteries plus an additional 8% discount at checkout with no minimum order value. All EU users are covered by 30 days price protection policy to ensure they secure the best available price during the promotion. Get your Battery Coupon Code: BlackFriday8% Of particular note is the WattCycle 12V 314Ah battery, featured as the most heavily discounted product in the 2025 Black Friday sales. The battery is offered at €489,99 (was €1.299,99), representing a 60% discount. After using the "BlackFriday8%" battery coupon code only €450.79. This battery delivers 4.019Wh of usable energy and engineered with advanced 200A BMS and EV A+ Grade cells rated for 15.000+ cycles, offering a reliable long-term power solution for diverse applications. WattCycle Marine Solution The European boating season underscores the need for dependable, lightweight power. WattCycle 12V 100Ah TM Blueto
JPMorganChase Announces Intention to Build a New Three-Million Sq Ft Landmark Tower in London27.11.2025 08:00:00 EET | Press release
JPMorganChase is proud to announce its intention to build a new three-million square feet tower in London. This transformative project would enable additional capacity for the firm to grow by creating a world-class workplace for up to 12,000employees, further strengthening London’s position as a global financial hub. The plans are subject to a continuing positive business environment in the UK and the receipt of the necessary approvals and agreements at a national and local level. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251126040802/en/ Artist's impression: The view from JPMorganChase's Riverside office Serving as the firm’s principal headquarters in the UK and its most significant presence in EMEA, the building would be situated on the Riverside development in Canary Wharf. The plans will provide employees and clients with a first-class working environment against a backdrop of uninterrupted views across the River Th
Vietnam’s C4IR and Ant International Partner to Accelerate Innovation as Ho Chi Minh City Eyes Becoming International Financial Centre27.11.2025 05:46:00 EET | Press release
The Vietnam Centre for the Fourth Industrial Revolution (C4IR Vietnam), established by the World Economic Forum and the People’s Committee of Ho Chi Minh City, and Ant International today announced a strategic partnership through a Memorandum of Understanding (MoU) to advance Vietnam’s digital economy, foster innovation, and support Ho Chi Minh City’s (HCMC) ambition to become an international financial centre and regional fintech hub. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251126280083/en/ The partnership was announced at the Ho Chi Minh City Economic Forum 2025, officiated by Vietnam’s Prime Minister Pham Minh Chinh and Chairman of the Ho Chi Minh City People’s Committee Nguyen Van Duoc. As Vietnam emerges as one of Asia’s most dynamic engines of trade, travel, and inclusive digital finance, the collaboration between C4IR Vietnam and Ant International aims to accelerate the country’s Fourth Industrial Revolution ag
LambdaTest and SVAM International Inc. Announce Partnership to Transform Quality Engineering for Businesses26.11.2025 19:00:00 EET | Press release
LambdaTest, a Gen-AI native quality engineering platform, announced a partnership with SVAM International, Inc., a global leader in digital transformation services. This strategic alliance marks a significant step forward in their mission to transform quality engineering for businesses worldwide. The partnership allows LambdaTest to extend its AI-native quality engineering capabilities into SVAM’s extensive digital transformation ecosystem. By integrating with SVAM’s experience in large-scale application development, testing, and delivery across major New York State and City agencies, as well as their platform expertise across Salesforce, ServiceNow, and Dynamics365, LambdaTest will empower more enterprises to modernize their software delivery pipelines. With LambdaTest’s intelligent test orchestration and execution engine at the core, teams can test smarter, accelerate release cycles, and achieve faster time-to-market at scale. Founded in 2017, LambdaTest is headquartered in San Franc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom